Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics

被引：67
作者：
Dinavahi, Saketh S. [1 ,5 ]
Bazewicz, Christopher G. [3 ,5 ]
Gowda, Raghavendra [1 ,5 ,6 ,7 ]
Robertson, Gavin P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA
[2] Penn State Univ, Coll Med, Dept Pathol, Hershey, PA 17033 USA
[3] Penn State Univ, Coll Med, Dept Dermatol, Hershey, PA 17033 USA
[4] Penn State Univ, Coll Med, Dept Surg, Hershey, PA 17033 USA
[5] Penn State Univ, Coll Med, Penn State Melanoma & Skin Canc Ctr, Hershey, PA 17033 USA
[6] Penn State Univ, Coll Med, Penn State Melanoma Therapeut Program, Hershey, PA 17033 USA
[7] Penn State Univ, Coll Med, Foreman Fdn Melanoma Res, Hershey, PA 17033 USA
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2019年 / 40卷 / 10期
关键词：
STEM-CELL MARKER; SELECTIVE INHIBITORS; INITIATING CELLS; EXPRESSION; ALDH1; RESISTANCE; MECHANISM; TARGET; 1A1; ACTIVATION;
D O I：
10.1016/j.tips.2019.08.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aldehyde dehydrogenases (ALDHs) are highly expressed in the chemotherapy- and radiotherapy-resistant cell subpopulations of many different cancer types. Accordingly, the development of ALDH inhibitors may be the most direct approach to target these cell populations. However, inhibiting multiple ALDH family members can be toxic and isoform-specific inhibition is often ineffective. This review discusses the role of ALDH in cancer and therapy resistance, and then overviews the various available ALDH inhibitors with a focus on the clinical potential ant limitations of these agents as cancer therapeutics. Finally, challenges and future research direrctions to effectively target ALDH in the management of cancer therapy resistance are discussed.
引用
收藏
页码：774 / 789
页数：16
相关论文
共 75 条
  • [1] ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients
    Ajani, J. A.
    Wang, X.
    Song, S.
    Suzuki, A.
    Taketa, T.
    Sudo, K.
    Wadhwa, R.
    Hofstetter, W. L.
    Komaki, R.
    Maru, D. M.
    Lee, J. H.
    Bhutani, M. S.
    Weston, B.
    Baladandayuthapani, V.
    Yao, Y.
    Honjo, S.
    Scott, A. W.
    Skinner, H. D.
    Johnson, R. L.
    Berry, D.
    [J]. MOLECULAR ONCOLOGY, 2014, 8 (01) : 142 - 149
  • [2] Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species
    Allison, Sarah E.
    Chen, Yongjuan
    Petrovic, Nenad
    Zhang, Jian
    Bourget, Kirsi
    Mackenzie, Peter I.
    Murray, Michael
    [J]. BIOCHEMICAL PHARMACOLOGY, 2017, 143 : 79 - 89
  • [3] High ALDH Activity Identifies Chemotherapy-Resistant Ewing's Sarcoma Stem Cells That Retain Sensitivity to EWS-FLI1 Inhibition
    Awad, Ola
    Yustein, Jason T.
    Shah, Preeti
    Gul, Naheed
    Katuri, Varalakshmi
    O'Neill, Alison
    Kong, Yali
    Brown, Milton L.
    Toretsky, Jeffrey A.
    Loeb, David M.
    [J]. PLOS ONE, 2010, 5 (11):
  • [4] Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer
    Bazewicz, Christopher G.
    Dinavahi, Saketh S.
    Schell, Todd D.
    Robertson, Gavin P.
    [J]. IMMUNOLOGY, 2019, 156 (01) : 47 - 55
  • [5] Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
    Bista, Ranjan
    Lee, David W.
    Pepper, Oliver B.
    Azorsa, David O.
    Arceci, Robert J.
    Aleem, Eiman
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36 : 1 - 14
  • [6] Aldehyde Dehydrogenase 7A1 (ALDH7A1) Is a Novel Enzyme Involved in Cellular Defense against Hyperosmotic Stress
    Brocker, Chad
    Lassen, Natalie
    Estey, Tia
    Pappa, Aglaia
    Cantore, Miriam
    Orlova, Valeria V.
    Chavakis, Triantafyllos
    Kavanagh, Kathryn L.
    Oppermann, Udo
    Vasiliou, Vasilis
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (24) : 18452 - 18463
  • [7] DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis
    Brooks, PJ
    Theruvathu, JA
    [J]. ALCOHOL, 2005, 35 (03) : 187 - 193
  • [8] ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/β-catenin pathway
    Calderaro, Julien
    Nault, Jean-Charles
    Bioulac-Sage, Paulette
    Laurent, Alexis
    Blanc, Jean-Frederic
    Decaens, Thomas
    Zucman-Rossi, Jessica
    [J]. VIRCHOWS ARCHIV, 2014, 464 (01) : 53 - 60
  • [9] ALDH2 polymorphism and alcohol-related cancers in Asians: a public health perspective
    Chang, Jeffrey S.
    Hsiao, Jenn-Ren
    Chen, Che-Hong
    [J]. JOURNAL OF BIOMEDICAL SCIENCE, 2017, 24
  • [10] β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids
    Condello, S.
    Morgan, C. A.
    Nagdas, S.
    Cao, L.
    Turek, J.
    Hurley, T. D.
    Matei, D.
    [J]. ONCOGENE, 2015, 34 (18) : 2297 - 2308
12345678